Editas Medicine (EDIT) to Release Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT) is expected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Editas Medicine to post earnings of ($0.43) per share and revenue of $37.17 million for the quarter.

Editas Medicine Stock Performance

Editas Medicine stock opened at $1.92 on Monday. The firm has a market capitalization of $158.08 million, a PE ratio of -0.75 and a beta of 1.94. Editas Medicine has a one year low of $1.12 and a one year high of $11.58. The stock’s 50 day moving average price is $1.37 and its 200 day moving average price is $2.56.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Wells Fargo & Company cut shares of Editas Medicine from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $7.00 to $4.00 in a research report on Wednesday, December 11th. Barclays cut their price objective on shares of Editas Medicine from $5.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, December 13th. Evercore ISI lowered their target price on Editas Medicine from $7.00 to $5.00 and set an “outperform” rating for the company in a research note on Monday, December 16th. Bank of America cut Editas Medicine from a “buy” rating to an “underperform” rating and cut their price target for the stock from $13.00 to $1.00 in a research note on Monday, November 25th. Finally, JPMorgan Chase & Co. lowered Editas Medicine from a “neutral” rating to an “underweight” rating in a research note on Monday, December 16th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.00.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.